Jessica J Lin

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 30

Top Topics

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Top Venues

Cancer discovery

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Clinical cancer research : an official journal of the American Association for Cancer Research

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa Lynne Johnson, Benjamin Besse, D Ross Camidge, Toshio Fujino, Satoshi Yoda, Linh Nguyen-Phuong, Hayato Mizuta, Ludovic Bigot, Catline Nobre, Jii Bum Lee, Mi Ra Yu, Scot Mente, Yuting Sun, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Enriqueta Felip Font, Byoung Chul Cho, Luc Friboulet, Aaron N Hata, Henry E Pelish, Alexander E Drilon
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer discovery (2024)
Mary C Boulanger, Jaime L Schneider, Jessica J Lin
Advances and future directions in ROS1 fusion-positive lung cancer. The oncologist (2024)
Sarah Waliany, Jessica J Lin
Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Jessica J Lin, Justin F Gainor, Vincent K Lam, Christine M Lovly
Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease. Cancer discovery 14 (6) (2024)
Sarah Waliany, Jessica J Lin
Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Sarah Waliany, Jessica J Lin
Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Sarah Waliany, Jessica J Lin
Taletrectinib: TRUST in the Continued Evolution of Treatments for ROS1 Fusion-Positive Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (22) (2024)
Jaime L Schneider, Khvaramze Shaverdashvili, Mari A Mino-Kenudson, Subba R Digumarthy, Andrew Do, Audrey Liu, Justin F Gainor, Jochen K Lennerz, Timothy F Burns, Jessica J Lin
Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution. NPJ precision oncology 7 (1) (2023)
Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Faria M Siddiqui, Nicole Phan, Pégah Jalili, Daria Timonina, Samantha Bilton, Maria Gomez-Caraballo, Hannah L Archibald, Varuna Nangia, Kristin Dionne, Amanda K Riley, Matthew Lawlor, Mandeep Kaur Banwait, Rosemary G Cobb, Lee Zou, Nicholas J Dyson, Christopher J Ott, Cyril H Benes, Gad Getz, Chang S Chan, Alice T Shaw, Justin F Gainor, Jessica J Lin, Lecia V Sequist, Zofia Piotrowska, Beow Y Yeap, Jeffrey A Engelman, Jake June-Koo Lee, Yosef E Maruvka, Rémi Buisson, Michael S Lawrence, Aaron N Hata
Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Jaime L Schneider, Jessica J Lin, Alice T Shaw
ALK-positive lung cancer: a moving target. Nature cancer (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Alexander E Drilon, Daniel Shao-Weng Tan, Ulrik N Lassen, Serge Leyvraz, Yongmei Liu, Jyoti D Patel, Lee S Rosen, Benjamin Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Lin Shen, Victor Moreno, Shivaani Kummar, Jessica J Lin
Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO precision oncology 6 (2022)
Ibiayi Dagogo-Jack, Geoffrey R Oxnard, Makenzi Evangelist, Subba R Digumarthy, Jessica J Lin, Justin F Gainor, John F Murphy, Michael S Rabin, Rebecca S Heist, Alona Muzikansky, Alice T Shaw
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. JCO precision oncology 6 (2022)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Aya Shiba-Ishii, Ted W Johnson, Ibiayi Dagogo-Jack, Mari A Mino-Kenudson, Theodore R Johnson, Ping Wei, Scott L Weinrich, Michele A McTigue, Makeba A Walcott, Linh Nguyen-Phuong, Kristin Dionne, Adam Acker, Lesli A Kiedrowski, Andrew Do, Jennifer L Peterson, Jaimie L Barth, Beow Y Yeap, Justin F Gainor, Jessica J Lin, Satoshi Yoda, Aaron N Hata
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nature cancer 3 (6) (2022)
Alissa J Cooper, Lecia V Sequist, Jessica J Lin
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nature reviews. Clinical oncology 19 (8) (2022)
Jessica J Lin, Justin F Gainor
Selective Targeting of RET Fusions in Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
George D Demetri, Filippo De Braud, Alexander E Drilon, Salvatore Siena, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn, Chao-Hua Chiu, Jessica J Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany Pitcher, David Chen, Timothy R Wilson, Christian Rolfo
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (7) (2022)
Harshabad Singh, Yvonne Y Li, Liam F Spurr, Atul B Shinagare, Ritika Abhyankar, Emma Reilly, Lauren K Brais, Anwesha Nag, Matthew D Ducar, Aaron R Thorner, Geoffrey I Shapiro, Rachel B Keller, Cheta Siletti, Jeffrey W Clark, Anna F Farago, Jessica J Lin, George D Demetri, Rahul Gujrathi, Matthew H Kulke, Laura E MacConaill, Azra H Ligon, Ewa Sicinska, Matthew L Meyerson, Jeffrey A Meyerhardt, Andrew D Cherniack, Brian M Wolpin, Kimmie Ng, Marios Giannakis, Jason L Hornick, James M Cleary
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (6) (2021)
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do, Jennifer Peterson, Kylie Prutisto Chang, Wafa Malik, Harper G Hubbeling, Adam Langenbucher, Adam J Schoenfeld, Christina J Falcon, Jennifer S Temel, Lecia V Sequist, Beow Y Yeap, Jochen K Lennerz, Alice T Shaw, Michael S Lawrence, Sai-Hong Ignatius Ou, Aaron N Hata, Alexander E Drilon, Justin F Gainor
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Noritaka Tanaka, Jessica J Lin, Chendi Li, Meagan B Ryan, Junbing Zhang, Lesli A Kiedrowski, Alexa G Michel, Mohammed U Syed, Katerina A Fella, Mustafa Sakhi, Islam Baiev, Dejan Juric, Justin F Gainor, Samuel J Klempner, Jochen K Lennerz, Giulia Siravegna, Liron Bar-Peled, Aaron N Hata, Rebecca S Heist, Ryan B Corcoran
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer discovery 11 (8) (2021)
Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K Lennerz, Adam Langenbucher, Jessica J Lin, Marguerite M Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A Adams, Beow Y Yeap, Emily Chin, Andrew Do, Hetal D Marble, Sara E Stevens, Subba R Digumarthy, Ashish Saxena, Rebecca J Nagy, Cyril H Benes, Christopher G Azzoli, Michael S Lawrence, Justin F Gainor, Alice T Shaw, Aaron N Hata
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (11) (2020)
Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, Rebecca J Nagy, Beow Y Yeap, Harper G Hubbeling, Emily Chin, Jennifer Ackil, Anna F Farago, Aaron N Hata, Jochen K Lennerz, Justin F Gainor, Richard B Lanman, Alice T Shaw
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. Clinical cancer research : an official journal of the American Association for Cancer Research 25 (22) (2019)
Zofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, Justin F Gainor, Inga T Lennes, Viola W Zhu, Nicolas Marcoux, Mandeep K Banwait, Subba R Digumarthy, Wenjia Su, Satoshi Yoda, Amanda K Riley, Varuna Nangia, Jessica J Lin, Rebecca J Nagy, Richard B Lanman, Dora Dias-Santagata, Mari Mino-Kenudson, A John Iafrate, Rebecca S Heist, Alice T Shaw, Erica K Evans, Corinne Clifford, Sai-Hong I Ou, Beni Wolf, Aaron N Hata, Lecia V Sequist
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer discovery 8 (12) (2018)
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, Benjamin J Burke, Luc Friboulet, Adam Langenbucher, Leila Dardaei, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack, Sergei Timofeevski, Harper G Hubbeling, Justin F Gainor, Lorin A Ferris, Amanda K Riley, Krystina E Kattermann, Daria Timonina, Rebecca S Heist, A John Iafrate, Cyril H Benes, Jochen K Lennerz, Mari Mino-Kenudson, Jeffrey A Engelman, Ted W Johnson, Aaron N Hata, Alice T Shaw
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer discovery 8 (6) (2018)
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J Lin, Viola W Zhu, Myung-Ju Ahn, D Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K Lim, Shanna Stopatschinskaja, David M Hyman, Robert C Doebele, J Jean Cui, Alice T Shaw
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer discovery 8 (10) (2018)